Changes in brain natriuretic peptide in chronic heart failure patients treated with long-acting versus short-acting loop diuretics: J-MELODIC subanalysis

What Was Tested

The paper reports a study of BNP (Nesiritide), published as a randomized controlled trial.

However, the mechanisms of the difference have not been elucidated.

The researchers reviewed changes in plasma BNP level and echo-assessed LV functional parameters from baseline to a year after the entry in 288 CHF patients with New York Heart Association class II or III symptoms that joined J-MELODIC.

Who Took Part

According to the abstract, 288 patients were involved.

The age groups tagged for this paper are middle-aged adults, older adults and people over 80, both men and women.

How the Study Was Run

The design is described as randomized and multicenter.

Because people in this BNP (Nesiritide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

More than one site took part, so the patients came from several places.

What Was Measured

The researchers reviewed changes in plasma BNP level and echo-assessed LV functional parameters from baseline to a year after the entry in 288 CHF patients with New York Heart Association class II or III symptoms that joined J-MELODIC.

The subject headings attached to it are Biomarkers, Chronic Disease, Echocardiography, Furosemide, Heart Failure, Japan and Natriuretic Peptide, Brain.

Author keywords: Brain natriuretic peptide, Chronic heart failure, Left ventricular ejection fraction and Loop diuretics.

What This Means in Plain Language

The paper is a randomized and multicenter study of BNP (Nesiritide) in 288 patients.

The publication is from 2017 (Heart and vessels), a journal based in Japan.

More context: the BNP (Nesiritide) compound page, all human trials.